We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$374M
AUM Growth
+$40.4M
Cap. Flow
-$815K
Cap. Flow %
-0.22%
Top 10 Hldgs %
86.42%
Holding
21
New
3
Increased
2
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$10.3M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$6.92M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.27M
4
MTVA
MetaVia Inc
MTVA
+$2.23M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$370K

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$20M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.38M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$1.52M

Sector Composition

Rank Sector Weight
1 Healthcare 97.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ECYT
1
DELISTED
Endocyte, Inc. Common Stock
ECYT
$74.8M 19.97%
4,211,302
-88,698
-2% -$1.52M
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$53.1M 14.19%
1,415,391
– –
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$40.6M 10.85%
2,252,460
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$35.7M 9.54%
504,210
– –
TCDA
5
DELISTED
Tricida, Inc. Common Stock
TCDA
$29.4M 7.85%
962,696
– –
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.36B
$24.8M 6.62%
3,249,164
+784,923
+32% +$5.27M
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$18M 4.8%
362,010
– –
KALV
8
DELISTED
KalVista Pharmaceuticals
KALV
$16.8M 4.48%
+759,181
New +$10.3M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$4.92B
$16.3M 4.35%
639,230
– –
DBVT
10
DBV Technologies
DBVT
$870M
$14.1M 3.76%
46,315
– –
RARX
11
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$9.85M 2.63%
544,612
– –
ARGX icon
12
argenx
ARGX
$53.8B
$9.19M 2.45%
121,581
-225,211
-65% -$20M
MNTA
13
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.91M 1.85%
262,822
-162,178
-38% -$4.38M
SPRO icon
14
Spero Therapeutics
SPRO
$91.5M
$4.98M 1.33%
474,015
– –
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.89M 1.31%
+726,677
New +$6.92M
KDMN
16
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.71M 1.26%
1,411,428
– –
BLPH
17
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$4.48M 1.2%
276,625
– –
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.97M 1.06%
99,309
+12,999
+15% +$370K
MTVA
19
MetaVia Inc
MTVA
$8.83M
$1.06M 0.28%
+8
New +$2.23M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$528K 0.14%
29,710
– –
CCXI
21
DELISTED
ChemoCentryx, Inc.
CCXI
$292K 0.08%
23,064
– –

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q3 2018 Portfolio in Review

As of Q3 2018, VHCP Management II held 21 positions worth $374M, up 12% from $334M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management II's Q3 2018 filing shows 3 new, 2 increased and 3 reduced positions. Its largest new stake was KalVista Pharmaceuticals: 759,181 shares worth $16.8M. The largest sale was argenx, an estimated $20M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

  • VHCP Management II's largest Q3 2018 buy was KalVista Pharmaceuticals: 759,181 shares worth $16.8M.
  • VHCP Management II added most to BioCryst Pharmaceuticals in Q3 2018, an estimated $5.27M increase.
  • VHCP Management II's biggest Q3 2018 reduction was argenx, cutting an estimated $20M.
  • VHCP Management II's ten largest holdings make up 86% of its $374M portfolio in Q3 2018.
  • VHCP Management II opened 3 new positions and closed 0 in Q3 2018.
  • VHCP Management II's portfolio value rose 12% quarter-over-quarter to $374M.

Based on VHCP Management II's 13F filing for Q3 2018, filed 13 Nov 2018.